Study of Zilovertamab Vedotin with Standard Treatment for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL)

Inclusion Criteria

• Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL).
• Cancer can be measured by scans according to specific criteria.
• General health status allows participation, with a performance score between 0 and 2.
• Adequate organ function.
• Able to provide a tumor sample for analysis.

For Zilovertamab Vedotin plus R-GemOx, or R-GemOx study arms:

• DLBCL has returned or not responded to treatment, and the patient is not eligible for or has not succeeded with a stem-cell transplant.
• Has not succeeded with CAR-T cell therapy or is not eligible for it.

Exclusion Criteria

• Has had a solid organ transplant.
• Diagnosed with primary mediastinal B-cell lymphoma (PMBCL).
• Has serious heart disease or irregular heartbeat needing medication.
• Has ongoing graft-versus-host disease (GVHD) or is being treated for it.
• Has fluid around the heart or lungs that is significant.
• Has nerve damage greater than Grade 1.
• Has had another cancer unless treated and cancer-free for 2 years.
• Has a specific nerve disease called Charcot-Marie-Tooth disease.
• Allergic to any part of the study treatment.
• Has had cancer treatment or investigational drugs within 4 weeks before starting the study.
• Has had radiation therapy within 4 weeks before starting the study and has not fully recovered.
• Is on ongoing steroid treatment.
• Has had a live vaccine within 30 days before starting the study.
• Is in another clinical trial or has used an investigational device within 4 weeks before starting the study.
• Has active lymphoma in the central nervous system (CNS) unless in remission.
• Has an active infection needing treatment.
• Has HIV or active Hepatitis C infection.
• Has a psychiatric or substance abuse disorder that would interfere with the study.